Table 2. Multiple regression analysis adjusted for centre, gender, age, BMI, and length of treatment, comparing imatinib versus nilotinib group.
| Imatinib group (n. 92) | Nilotinib group (n. 36) | ||
|---|---|---|---|
| Coefficient (95% CI)* | P-value* | ||
| FPG (mg/dl) | Reference | 9.8 (1.9; 17.8) | 0.015 |
| Insulin (%) | Reference | 17.4 (6.2; 30.3) | 0.002 |
| C-peptide (%) | Reference | 11.6 (4.1; 19.7) | 0.002 |
| HOMA-IR (%) | Reference | 22.1 (9.4; 37.7) | <0.001 |
| HOMA-%B (%) | Reference | 2.0 (−9.5; 10.5) | 0.76 |
| Total cholesterol (%) | Reference | 11.6 (7.3; 16.2) | <0.001 |
| HDL cholesterol (%) | Reference | 6.2 (1.0; 11.6) | 0.02 |
| Triglycerides (%) | Reference | 3.6 (−5.8; 13.9) | 0.48 |
| LDL cholesterol (mg/dl) | Reference | 42.4 (27.0; 57.8) | <0.001 |
| OR (95% CI)** | P-value** | ||
| DM/IFG | Reference | 1.7 (0.5; 5.8) | 0.39 |
| MS | Reference | 0.6 (0.2; 2.4) | 0.46 |
BMI= body mass index; CI= confidence interval; OR= odds ratio; FPG= fasting plasma glucose; HOMA-IR= Homeostasis Model Assessment – Insulin Resistance; HOMA-%B= Homeostasis Model Assessment – β-cell function; DM= diabetes mellitus; IFG= impaired fasting glucose; MS= metabolic syndrome.
*
From multiple linear regression models.
**
From multiple logistic regression models.